Skip to Content
Merck
  • Dibenzofuran Derivatives Inspired from Cercosporamide as Dual Inhibitors of Pim and CLK1 Kinases.

Dibenzofuran Derivatives Inspired from Cercosporamide as Dual Inhibitors of Pim and CLK1 Kinases.

Molecules (Basel, Switzerland) (2021-11-14)
Viet Hung Dao, Isabelle Ourliac-Garnier, Cédric Logé, Florence O McCarthy, Stéphane Bach, Teresinha Gonçalves da Silva, Caroline Denevault-Sabourin, Jérôme Thiéfaine, Blandine Baratte, Thomas Robert, Fabrice Gouilleux, Marie Brachet-Botineau, Marc-Antoine Bazin, Pascal Marchand
ABSTRACT

Pim kinases (proviral integration site for Moloney murine leukemia virus kinases) are overexpressed in various types of hematological malignancies and solid carcinomas, and promote cell proliferation and survival. Thus, Pim kinases are validated as targets for antitumor therapy. In this context, our combined efforts in natural product-inspired library generation and screening furnished very promising dibenzo[b,d]furan derivatives derived from cercosporamide. Among them, lead compound 44 was highlighted as a potent Pim-1/2 kinases inhibitor with an additional nanomolar IC50 value against CLK1 (cdc2-like kinases 1) and displayed a low micromolar anticancer potency towards the MV4-11 (AML) cell line, expressing high endogenous levels of Pim-1/2 kinases. The design, synthesis, structure-activity relationship, and docking studies are reported herein and supported by enzyme, cellular assays, and Galleria mellonella larvae testing for acute toxicity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Staurosporine from Streptomyces sp., for molecular biology, ≥95% (HPLC)
Sigma-Aldrich
CHR-6494 trifluoroacetate salt, ≥98% (HPLC)
Sigma-Aldrich
Indirubin-3′-oxime, ≥98% (HPLC), solid